
GHRS Stock Forecast & Price Target
GHRS Analyst Ratings
Bulls say
GH Research PLC has exhibited a strong efficacy profile for its lead candidate, GH001, showing significant improvements in the MADRS scale at Day 2 and Day 8, indicating robust therapeutic potential for treatment-resistant depression. Additionally, the company reports a rapid remission rate of 57.5% within just two hours, which increases to 70% by Day 2, highlighting the quick onset of effect associated with its proprietary therapies. With an estimated enterprise value of $500 million, there is potential for upside as the clinical landscape for psychedelic therapies, particularly in TRD, continues to evolve positively, further bolstering GH Research's long-term outlook.
Bears say
GH Research PLC faces significant challenges that contribute to a negative outlook on its stock. The company's therapies in development have shown inferior efficacy compared to a competitor, with low remission and response rates of only 2.4% to 4.9%, highlighting potential difficulties in achieving clinical success. Furthermore, GH Research is expected to incur net losses until product approval and during the early launch phase, compounded by commercial risks related to slower adoption rates and competitive pressures, which could impact pricing strategies.
This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.
GHRS Analyst Forecast & Price Prediction
Start investing in GHRS
Order type
Buy in
Order amount
Est. shares
0 shares